25 results about "Drug Utilization" patented technology

This invention provides a chemotherapy catheter for spinal tuberculosis, comprising a catheter with a drug channel, a flexible tube at the front end of the catheter with multiple through holes communicating with the drug channel, and a built-in one-way structure. The one-way structure includes an elastic rubber sheet at one end fixed to the inner wall of the drug channel; multiple elastic rubber sheets are stacked together in a conical shape; and a connector is connected to the rear end of the catheter, with a drug injection end for injecting medication. This invention, by inserting the catheter into the patient's body, injects medication through the drug injection end, which then passes through the drug channel and the one-way structure to prevent backflow, and finally flows out through the multiple through holes, thereby widely dispersing the medication and improving drug utilization.

The present application relates to the technical field of medicine and provides a lanosterol derivative, a preparation method therefor and a use thereof. The structural formula of the lanosterol derivative provided by the present application is as shown in formula I or II. The lanosterol derivative provided by the present application has both lipid solubility and water solubility, and can effectively penetrate into the pathological site in the body, thereby improving the drug utilization rate. The results of embodiments show that the lanosterol derivative provided by the present application has a significantly higher solubility in water than lanosterol or 25-hydroxylanosterol and shows a significant therapeutic effect on a cataract in animal in vivo experiments. Therefore, the derivative has wide prospects in the preparation of drugs for treating eye diseases or conditions.

The application discloses a drug design method and device based on topological data analysis, equipment and medium, relates to the technical field of computer-aided drug design, and the method comprises the steps of obtaining a plurality of three-dimensional structure conformations of a target protein, determining the binding pocket region of each three-dimensional structure conformation, and constructing a conformation set; calculating a topological descriptor representing the topological relationship between atoms based on the atomic coordinates of the binding pocket region of each three-dimensional structure conformation, and converting the topological descriptor into a corresponding conformation feature vector; performing a pooling operation on the conformation feature vector corresponding to each three-dimensional structure conformation to generate a unified topological feature representation representing the common topological feature mode of the target protein binding pocket under a plurality of three-dimensional structure conformations; and screening or generating candidate drugs based on the unified topological feature representation. The common topological invariant information of a plurality of conformations is used to represent the flexible protein binding pocket, the screening omission caused by single conformation representation is reduced, and the representation accuracy and the calculation efficiency are considered.

This invention belongs to the field of DNA hydrogel technology, specifically relating to a VEGF-responsive, on-demand release smart DNA hydrogel of glycyrrhizin, its preparation method, and its applications. This invention constructs a VEGF-responsive smart DNA hydrogel, efficiently encapsulating glycyrrhizin within a three-dimensional gel network, utilizing the high expression of VEGF in the tumor microenvironment to trigger on-demand drug release. This invention achieves precise on-demand release of glycyrrhizin, significantly improving drug utilization efficiency and reducing systemic toxicity. Simultaneously, the VEGF aptamer introduced into the system can specifically bind to and neutralize free VEGF, blocking angiogenesis, cutting off tumor nutrient supply, and further inhibiting tumor proliferation and progression, achieving a synergistic effect of intelligent drug delivery and anti-angiogenesis.

This invention discloses a cinnamic acid-black phosphorus nanocomposite targeting Aβ, its preparation method, and its application. The composition uses 4-(dimethylamino)cinnamic acid as the Aβ-targeting group and consists of a drug-loaded host (BP, black phosphorus nanosheets), a modifying material C18-PEG-NH2 (amino polyethylene glycol stearic acid), a targeting material Tar (4-(dimethylamino)cinnamic acid), and a therapeutic material Cur (curcumin). The preparation method includes the following steps: (1) preparation of PEG-Tar, (2) preparation of PEG-Tar@Cur, and (3) preparation of the BP-PEG-Tar@Cur composition. This invention utilizes black phosphorus nanosheets to load Curcumin, whose excellent specific surface area significantly increases the drug loading capacity. Furthermore, by using 4-(dimethylamino)cinnamic acid as a group targeting Aβ, diffuse distribution of the drug in the brain is avoided, greatly improving the drug utilization rate of Curcumin. The synthesis process of this invention is simple, highly reproducible, and easy to scale up for industrial application, and it has a positive effect in the treatment of Alzheimer's disease.

The present application relates to the technical field of medicine and provides a lanosterol derivative, a preparation method therefor and a use thereof. The structural formula of the lanosterol derivative provided by the present application is as shown in formula I or II. The lanosterol derivative provided by the present application has both lipid solubility and water solubility, and can effectively penetrate into the pathological site in the body, thereby improving the drug utilization rate. The results of embodiments show that the lanosterol derivative provided by the present application has a significantly higher solubility in water than lanosterol or 25-hydroxylanosterol and shows a significant therapeutic effect on a cataract in animal in vivo experiments. Therefore, the derivative has wide prospects in the preparation of drugs for treating eye diseases or conditions.

The application discloses a kind of lipopeptide class for preventing and treating walnut rot disease and preparation method thereof, it is related to plant disease control technical field, including the nanocarrier core of lipopeptide class loading;And the responsive material shell of the carrier core outside is covered;Wherein, the responsive material shell can be degraded under the microenvironment of walnut tree disease site, the microenvironment characteristics include pH value is lower than 6.0 and there is pectinase activity.The present application realizes the precise and efficient prevention and treatment of walnut rot disease by constructing the intelligent nanometer drug delivery system of "nuclear shell structure", realizes the targeting and on-demand release of lipopeptide in lesion site using the shell with double response to disease microenvironment, greatly improves drug utilization and prolongs the effective period;Nanocarrier core effectively protects lipopeptide activity, and its 50-200 nanometer optimized particle size and surface modification promote drug delivery and enrichment in tree body.

This invention belongs to the pharmaceutical field, and provides a chlorophyll derivative microneedle formulation, its preparation method, and its uses. The chlorophyll derivative microneedle formulation comprises the following raw materials by weight: 0.5-5 parts chlorophyll derivative, 5-20 parts excipient, 0.5-5 parts polysaccharide, and 70-94 parts solvent. The preparation method is as follows: the pH of the chlorophyll derivative dissolved in the solvent is adjusted to 6-8, and then the co-solvent, polysaccharide, and excipient are added to obtain a mixed solution; the mixed solution is loaded into a microneedle mold, vacuum-suctioned, and dried to obtain an integrated chlorophyll derivative needle. This microneedle can improve the targeted and transdermal drug delivery effect and drug utilization rate of the chlorophyll derivative, and the preparation method can improve the stability of the chlorophyll derivative and increase the local drug concentration at the affected area.

The present application belongs to the technical field of medicine crystal form, and particularly relates to a crystal form of lasmiditan-mellitic acid and a preparation method thereof. The crystal structure of the crystal form of lasmiditan-mellitic acid provided by the present application has a molar ratio of 1:1:2 of lasmiditan, mellitic acid and water, and an X-ray diffraction spectrum expressed in 2θ using Cu-Kα radiation has characteristic peaks at 6.59±0.2°, 10.73±0.2°, 16.14±0.2°, 23.62±0.2° and 24.10±0.2°. The crystal form is stable, has high solubility, is beneficial to the storage of the bulk drug, is beneficial to the improvement of the drug utilization, makes the drug better play a therapeutic role, has better tensile strength, improves the compression formability, and is convenient for the application of the preparation.

The application discloses a fumigation equipment treatment path planning system and a fumigation equipment, and applies to the technical field of intelligent medical treatment and Internet of Things. In the system, the biophysical parameters of each detection point in the detection area are acquired first, and whether the detection point is a to-be-treated detection point is judged, and then the treatment path is planned in combination with the number, position and starting point of the mechanical arm of the to-be-treated detection point. If it is a single to-be-treated detection point, the path is determined according to the position and the starting point of the mechanical arm, and the treatment execution parameter is set according to the corresponding parameter. If it is two or more, the path is optimized in combination with the weight coefficient, position and starting point of the mechanical arm of each point, and the execution parameter is configured according to the parameter difference of each point. The application can adaptively identify the position and number of lesions, realize dynamic planning of the treatment path of the mechanical arm, simultaneously set the treatment parameter based on the biophysical parameter, break the closed loop from sensing to execution, realize adaptive adjustment based on the real-time state of the patient, and improve the treatment accuracy, drug utilization rate and curative effect controllability.

The application provides a tumor inhibiting composition and a preparation method and application thereof, and belongs to the technical field of medicines. After mesoporous carbon nanotubes are oxidized and chlorinated, oleanolic acid dithiocarbamate conjugate and (2-hydroxypropyl)-beta-cyclodextrin are coupled, drugs are loaded, a protein liposome solution is added, ultrasonic treatment is carried out, centrifugal separation is carried out, unloaded drug-loaded carbon nanotubes are removed, supernatant is freeze-dried, and the tumor inhibiting composition is prepared. The tumor inhibiting composition greatly improves the drug loading capacity of the nanosystem, the synergistic effect of multiple drugs, the anti-tumor effect, realizes the effects of targeting, slow and controlled release of drugs, improves the drug utilization rate, reduces the intake amount of drugs, reduces side effects, and improves the compliance of patients.

The application discloses a special pacifier type atomizer for newborns, relates to the technical field of atomizers, and aims at the clinical pain points of the existing mask type atomizer, such as poor adaptation to newborns, low cooperation degree, low drug utilization rate and hidden safety hazards, and provides a special atomization scheme, and the technical key points are as follows: the special pacifier type atomizer is composed of an atomization host, a connecting pipeline, a liquid medicine storage bin and a pacifier type mist outlet, the components are detachably and sealably connected, and can be cleaned and disinfected respectively. The host adopts a micro ultrasonic atomization structure, can output precise mist droplets with a size of 3-5 microns, and has a power of 5-10 W which can be adjusted; the mist outlet is a human engineering pacifier structure imitating breast milk, active sucking administration is realized by using the sucking reflex of newborns, and the mouth and nose are not shielded. The device improves the drug utilization rate to 75%-85%, shortens the single treatment time to 5-10 minutes, greatly improves the treatment cooperation degree, eliminates safety hazards such as suffocation and skin damage, is suitable for 1-5 kg newborns, and can be used in multiple clinical scenes such as incubators.

This invention relates to the field of intelligent medical information technology, providing an information-based planning system for acne patients based on the IMB model. The system collects facial acne characteristics, medication adherence, and facial oil characteristics data from acne patients. It constructs a gridded oil-matching medication adherence index and a gridded acne condition index. Through oil secretion gradient weighted fusion and dynamic condition calibration, it outputs the facial gridded drug utilization rate results. Furthermore, it identifies the influencing factors of each facial grid and performs spatial aggregation to generate medication adherence planning instructions that match the individual's facial region characteristics. This invention forms a closed-loop process from condition gridded perception, multi-dimensional behavior quantification, drug utilization rate attribution assessment to regional targeted intervention. It achieves refined and intelligent acne medication management based on differences in facial oil secretion and lesion aggregation characteristics, significantly improving the accuracy of individualized intervention for acne patients' topical medication behavior.

In some embodiments, a method of automatically adjusting insulin therapy for a patient includes receiving, at a device associated with the patient, one or more glucose measurements generated by a continuous glucose monitoring (CGM) system of the patient for a period. The method also includes determining, at the device, basal insulin data and bolus insulin data of the patient for the period. The method also includes determining, at the device, a relationship between the basal insulin data and the bolus insulin data. The method also includes generating, at the device, an insulin therapy instruction for the patient based on the one or more glucose measurements and the determined relationship between the basal insulin data and the bolus insulin data, where the insulin therapy instruction includes a total bolus amount.

The present application relates to the field of nanobiomaterials, in particular to a drug-loaded nanovaccine and a preparation method and application thereof, so as to improve tumor treatment effect and biological safety. The drug-loaded nanovaccine comprises MIL-100(Fe) and a manganese-doped mesoporous silica carrier, the MIL-100(Fe) is coated on the outer surface of the manganese-doped mesoporous silica carrier, and the manganese-doped mesoporous silica carrier is loaded with sorafenib. The MF@SOR nanovaccine of the present application has very high biological safety. Meanwhile, the carrier of the present application is wrapped with a layer of MIL-100(Fe), the coating is very uniform and stable, which can further improve the bioavailability of sorafenib, maximize the use of drugs and reduce the toxic and side effects of drugs. In addition, the MF@SOR nanovaccine can also induce the body to produce immune memory, inhibit the recurrence and metastasis of tumors, the recurrence and metastasis of tumors are significantly reduced, and the treatment effect of tumors is significantly improved.

This invention relates to the field of biomaterials technology, and in particular to a neodysone-loaded liposome hydrogel, its preparation method, and its application. The preparation method includes: placing neodysone, lecithin, cholesterol, DSPE-polyethylene glycol 2000, and DSPE-polyethylene glycol 2000-cRGD in methanol, followed by stirring, sonication, and dialyzing to obtain neodysone liposomes; adding chitosan, acetic acid solution, and β-glycerophosphate disodium hydrate to the neodysone liposomes, adjusting the pH to 7-7.2, and obtaining the neodysone-loaded liposome hydrogel. This invention achieves cell-targeted and acid-triggered drug release through the synergistic effect of liposomes and hydrogel, and provides long-term intra-articular retention and sustained release. The two construct a multi-level drug delivery system of "active targeting-joint retention-acid-triggered release," significantly improving drug utilization and efficacy.

This invention relates to the field of medical preparations technology and discloses a topical medical preparation for inhibiting the proliferation of scar fibroblasts. The preparation comprises a thermosensitive phase change matrix and nanomicelles distributed therein. The thermosensitive phase change matrix undergoes a phase transition from sol to gel at 25°C to 32°C. The nanomicelles include polyethylene glycol segments, enzyme-sensitive chains, polylactic acid segments, and inhibitors linked by oxidation-responsive bonds. After the enzyme-sensitive chains sense and induce enzymatic cleavage of fibroblast-activating proteins, the nanomicelles expose a hydrophobic core and trigger oxidative cleavage of the oxidation-responsive bonds, releasing the inhibitor. This invention utilizes a thermosensitive phase change synergistic multi-level biochemical signal sensing mechanism to decouple the preparation's penetration depth from its biocompatibility. The preparation triggers targeted drug release only in the scar activation area, avoiding the toxic effects of the inhibitor on normal tissue and improving drug utilization at dermal lesions.

The present application relates to wastewater treatment technical field, specifically to a kind of wastewater treatment device and method based on dangerous chemical production.The box main body is provided with water inlet box for water inlet at one end of the box main body, and the water inlet box is connected with mixing box for drug mixing reaction at one end, and the mixing box is connected with treatment box for treating wastewater at the other end, and a plurality of connecting walls are symmetrically arranged on the side wall of the mixing box, and a plurality of moving cavities are formed between the connecting walls.The present application adopts horizontal and vertical double-dimension dynamic drug distribution structure, cooperates with variable-pitch screw rod to realize self-adaptive adjustment of injection pipe spacing with liquid level, high liquid level, low liquid level, avoids local imbalance of drug concentration, improves mixing uniformity and drug utilization rate, strengthens the neutralization, oxidation and flocculation reaction effect of dangerous chemical wastewater pollutants, and uses the reciprocating motion of the nozzle to cooperate with the conical self-cleaning structure, which can dredge the nozzle blockage impurities in real time and guide to discharge.

This utility model discloses an automated radiopharmaceutical dispensing and injection system. The system includes a housing, a control structure, a raw material processing structure, a fluid control structure, a waste liquid management structure, and a moving structure. The control structure is connected to the other structures and mounted on the housing, which is mounted on the moving structure. The control structure controls the operation of the raw material processing structure, the fluid control structure, and the waste liquid management structure, and immediately stops the corresponding structure functions in emergencies. The raw material processing structure stores and processes the radiopharmaceutical raw material, controlling its opening, closing, and needle insertion. The fluid control structure precisely controls the extraction and injection of the radiopharmaceutical raw material. The waste liquid management structure collects and stores waste liquid generated during extraction and injection. Implementing this system improves operational safety and accuracy while reducing costs and increasing drug utilization.

This invention provides a soluble microneedle, its preparation method, and its application. The microneedle comprises a tip and a base. The tip is made of a composite material cross-linked with silk fibroin and tannic acid, and the base is made of a biocompatible material loaded with single-atom iron nanozymes. During preparation, the tip layer and base layer materials are separately filled into a microneedle mold, cured, dried, and then demolded. This microneedle employs a layered design; the tip layer can persistently release tannic acid for anti-inflammatory and antioxidant effects, while the base layer rapidly releases single-atom iron nanozymes in the inflammatory microenvironment, catalyzing the generation of reactive oxygen species for highly efficient antibacterial activity. The microneedle of this invention can simultaneously act on infection, inflammation, and oxidative stress, significantly improving the treatment effect of bacterial keratitis, and has advantages such as good biocompatibility, high drug utilization, and safe and convenient use.

This invention discloses a soluble microneedle patch with drug-enriched needle tip and its preparation method, belonging to the field of microneedle technology. The preparation method includes: (1) preparing a drug-loaded solution using a hydrophilic drug and a soluble polymer as solutes, injecting the drug-loaded solution into the needle body part of a microneedle mold, and performing low-temperature centrifugal drying; (2) preparing a polymer solution using a soluble polymer as a solute, injecting the polymer solution into the remaining part of the microneedle mold, centrifuging and drying, and then demolding to obtain the soluble microneedle patch with drug-enriched needle tip. Compared with the conventional natural drying molding method, the two-step centrifugal drying method of this invention can enrich the drug at the tip of the microneedle, thereby enabling rapid release of the drug from the microneedle, improving drug utilization, and reducing waste caused by the inability of the soluble microneedle body to fully enter the skin. At the same time, the microneedles prepared using a soluble matrix avoid organic solvent residue, have good biocompatibility, and good puncture effect.

The present application relates to a soluble microneedle patch of semaglutide and a preparation method and use thereof. The soluble microneedle patch of semaglutide comprises a drug-loaded needle tip layer and a back plate layer; the drug-loaded needle tip layer comprises semaglutide and a needle tip layer matrix material; the weight percentage of the semaglutide is 85% to 92% and the weight percentage of the needle tip layer matrix material is 8% to 15% based on the total weight of the drug-loaded needle tip layer being 100%; and the needle tip layer matrix material is hyaluronic acid or a salt thereof. The soluble microneedle patch of semaglutide has excellent needle type, superior mechanical strength and skin puncture performance, high safety, fast drug release and penetration rate, and excellent drug utilization rate and bioavailability; the preparation method is simple, controllable, and suitable for large-scale production. In addition, the soluble microneedle patch of semaglutide is convenient and quick to administer, has high patient compliance, and has a broad clinical application prospect.

This invention relates to the field of surgical wound treatment materials and related instruments, and discloses an injectable hydrogel and injection method for wounds after tophi removal surgery, comprising a thermosensitive hydrogel matrix, a uric acid-lowering active ingredient, and an anti-inflammatory active ingredient; the thermosensitive hydrogel matrix is ​​selected from one or more of polylactic acid-polyethylene glycol-polylactic acid block copolymer, polylactic acid-glycolic acid copolymer-polyethylene glycol-polylactic acid-glycolic acid copolymer block copolymer, and poloxamer 407; the mass percentage concentration of the thermosensitive hydrogel matrix in the injectable hydrogel for wounds after tophi removal surgery is 15%-30%. Compared with existing oral or intravenous systemic drug administration regimens, the local sustained-release drug administration method of this invention avoids systemic drug side effects and improves the local drug utilization efficiency of the surgical cavity.

The application relates to the technical field of pharmaceutical preparation, and provides a metformin hydrochloride gastric floating sustained-release microtablet. The component composition of the metformin hydrochloride gastric floating sustained-release microtablet comprises, in percentage by weight, 50%-75% of metformin hydrochloride, 5%-20% of a skeleton material, 9%-18% of a filling agent, 2%-6% of a floating aid, 1%-4% of a lubricant and 1%-3% of a nano modifier. The metformin hydrochloride gastric floating sustained-release microtablet can prolong the residence time of metformin hydrochloride in the stomach and the upper part of the small intestine, and improve the drug utilization.